Kimberly A. O'NEill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kimberly A. O'NEill has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Lauren B. Krupp
Pediatric MS Center, NYU Langone Health, New York, New York, USA
7 shared publications - Aaron W. Abrams
Cleveland Clinic, OH
4 shared publications - Akash Virupakshaiah
Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco
3 shared publications - Claudia Gambrah-Lyles
Washington University in St. Louis, MO
3 shared publications - John W. Rose
Department of Neurology, University of Utah, Salt Lake City
3 shared publications - Kristen S. Fisher
Division of Pediatric Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston
3 shared publications
Latest Publications
- 9 November 2026
- Published by S. Karger AG in Neuroepidemiology
Comorbidity Burden and Social Determinants of Health Among U.S. Hospitalizations for Multiple Sclerosis: A National Inpatient Sample Analysis
Introduction: Individuals hospitalized with Multiple Sclerosis (MS) often experience comorbid conditions that affect their quality of life and also face social determinants of health (SDOH) that affect outcomes. Methods: Data were leveraged from the 2019 National Inpatient Sample database, a component of the Nationwide Healthcare Cost and Utilization Project, a government survey of hospitalizations across the US, and theoretically representative of all hospitalizations in the US. We compared patients hospitalized with MS to patients hospitalized without MS across demographic characteristics and common concomitant diagnoses. In a secondary analysis restricted to MS hospitalizations, we examined the association of comorbidities and SDOH with length of stay. Results: Between January 2019 and December 2019 there were a total of 25,155 hospitalizations for MS and 35,392,578 hospitalizations without MS. Mean age at admission was 45.9 years for MS versus 50.2 years for non-MS hospitalizations (p < 0.001). Patients hospitalized with MS were more likely to be female and more diverse than non-MS hospitalizations. Patients with MS were more likely to have a diagnosis of anxiety (18.9% versus 10.2%, p < 0.001), chronic pain (10.5% versus 5%, p < 0.001), and depression (21.8% versus 9.9%, p < 0.001) compared to non-MS hospitalizations. Among MS hospitalizations, depression diagnoses were reported less often among Black vs. non-Black (16.6% versus 23.6%, p < 0.001), Hispanic vs. Non-Hispanic (13.8% versus 22.7%, p < 0.001), and patients on Medicaid vs. non-Medicaid (19.1% versus 22.6%, p < 0.001). In a regression model restricted to MS patients, number of comorbidities and Black compared to non-Black race corresponded to increasing length of stay. Conclusion: MS patients have higher rates of anxiety, depression, and pain compared to non-MS patients. Minoritized groups with MS are less likely to be given a secondary diagnosis code for depression, anxiety or pain, possibly reflecting underdiagnosis of these conditions.
- 9 November 2026
- Published by S. Karger AG in Neuroepidemiology
Comorbidity Burden and Social Determinants of Health Among U.S. Hospitalizations for Multiple Sclerosis: A National Inpatient Sample Analysis
Introduction: Individuals hospitalized with Multiple Sclerosis (MS) often experience comorbid conditions that affect their quality of life and also face social determinants of health (SDOH) that affect outcomes. Methods: Data were leveraged from the 2019 National Inpatient Sample database, a component of the Nationwide Healthcare Cost and Utilization Project, a government survey of hospitalizations across the US, and theoretically representative of all hospitalizations in the US. We compared patients hospitalized with MS to patients hospitalized without MS across demographic characteristics and common concomitant diagnoses. In a secondary analysis restricted to MS hospitalizations, we examined the association of comorbidities and SDOH with length of stay. Results: Between January 2019 and December 2019 there were a total of 25,155 hospitalizations for MS and 35,392,578 hospitalizations without MS. Mean age at admission was 45.9 years for MS versus 50.2 years for non-MS hospitalizations (p < 0.001). Patients hospitalized with MS were more likely to be female and more diverse than non-MS hospitalizations. Patients with MS were more likely to have a diagnosis of anxiety (18.9% versus 10.2%, p < 0.001), chronic pain (10.5% versus 5%, p < 0.001), and depression (21.8% versus 9.9%, p < 0.001) compared to non-MS hospitalizations. Among MS hospitalizations, depression diagnoses were reported less often among Black vs. non-Black (16.6% versus 23.6%, p < 0.001), Hispanic vs. Non-Hispanic (13.8% versus 22.7%, p < 0.001), and patients on Medicaid vs. non-Medicaid (19.1% versus 22.6%, p < 0.001). In a regression model restricted to MS patients, number of comorbidities and Black compared to non-Black race corresponded to increasing length of stay. Conclusion: MS patients have higher rates of anxiety, depression, and pain compared to non-MS patients. Minoritized groups with MS are less likely to be given a secondary diagnosis code for depression, anxiety or pain, possibly reflecting underdiagnosis of these conditions.
- 27 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (8) , e218508
Comparative Effectiveness of Treatments for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Background and ObjectivesThe most effective treatment strategy to prevent relapses after a first myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) event remains unclear. Our o...
- 27 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (8) , e218508
Comparative Effectiveness of Treatments for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Background and ObjectivesThe most effective treatment strategy to prevent relapses after a first myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) event remains unclear. Our o...
- 8 October 2026
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 41 (10) , 1397-1398
Letter from the Guest Editor: Toward Equity in Child Neurology
- 8 October 2026
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 41 (10) , 1397-1398
Letter from the Guest Editor: Toward Equity in Child Neurology
- Open Access
- 24 June 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e91763
Adaptation of the Transition Readiness Assessment Questionnaire for Pediatric-Onset Multiple Sclerosis: Protocol for a User-Centered Design Approach
Background: Pediatric-onset multiple sclerosis (POMS) is a chronic, progressive neurologic condition requiring lifelong management and coordinated transition from pediatric to adult care. Evidence-based guidelines identify transition readiness assessment as a core component of successful transition; however, most POMS clinics do not formally assess readiness, and existing tools do not address POMS-specific challenges, such as fluctuating disability, complex treatment regimens, and cognitive impairment. This gap underscores the need for a transition readiness measure tailored to POMS. Objective: This paper aims to describe a stakeholder-engaged, implementation science–guided protocol for adapting the Transition Readiness Assessment Questionnaire (TRAQ) version 6.0 to reflect the unique developmental and clinical needs of youth with POMS. Methods: Using adaptation and participatory research as our guiding implementation strategies, surveys will be administered to patients, caregivers, and clinicians to identify barriers to and facilitators of transition to adult care and define essential self-management competencies in POMS. Survey content will be informed by constructs from the dynamic adaptation process framework and existing TRAQ 6.0 domains. Identified competencies will be refined using a Delphi consensus process. Through cognitive interviewing and a multidisciplinary focus group of collaborators, the adapted measure will be reviewed to assess clarity, relevance, and perceived clinical utility. Results: This project will generate a consensus-driven set of POMS-specific transition competencies and systematically adapt the TRAQ 6.0 to the POMS population. This study was funded in July 2025. The health care provider survey was disseminated in November 2025 across the 27 sites in the US Network of Pediatric Multiple Sclerosis Centers. The patient and caregiver surveys have been finalized, and distribution is projected to begin in June 2026, with a target of 15 patients and 15 caregivers. As of manuscript submission, no patients or caregivers have been recruited, and data analysis has not yet started. Data collection is expected to conclude by the end of 2026, and results are anticipated for publication in 2027. Conclusions: This protocol outlines a rigorous, replicable approach to adapting a validated transition readiness measure to POMS. The adapted TRAQ 6.0 will support evidence-based transition planning and inform future psychometric testing and implementation research to improve the care of patients with POMS as they age.
- 24 June 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e91763
Open AccessAdaptation of the Transition Readiness Assessment Questionnaire for Pediatric-Onset Multiple Sclerosis: Protocol for a User-Centered Design Approach
Background: Pediatric-onset multiple sclerosis (POMS) is a chronic, progressive neurologic condition requiring lifelong management and coordinated transition from pediatric to adult care. Evidence-based guidelines identify transition readiness assessment as a core component of successful transition; however, most POMS clinics do not formally assess readiness, and existing tools do not address POMS-specific challenges, such as fluctuating disability, complex treatment regimens, and cognitive impairment. This gap underscores the need for a transition readiness measure tailored to POMS. Objective: This paper aims to describe a stakeholder-engaged, implementation science–guided protocol for adapting the Transition Readiness Assessment Questionnaire (TRAQ) version 6.0 to reflect the unique developmental and clinical needs of youth with POMS. Methods: Using adaptation and participatory research as our guiding implementation strategies, surveys will be administered to patients, caregivers, and clinicians to identify barriers to and facilitators of transition to adult care and define essential self-management competencies in POMS. Survey content will be informed by constructs from the dynamic adaptation process framework and existing TRAQ 6.0 domains. Identified competencies will be refined using a Delphi consensus process. Through cognitive interviewing and a multidisciplinary focus group of collaborators, the adapted measure will be reviewed to assess clarity, relevance, and perceived clinical utility. Results: This project will generate a consensus-driven set of POMS-specific transition competencies and systematically adapt the TRAQ 6.0 to the POMS population. This study was funded in July 2025. The health care provider survey was disseminated in November 2025 across the 27 sites in the US Network of Pediatric Multiple Sclerosis Centers. The patient and caregiver surveys have been finalized, and distribution is projected to begin in June 2026, with a target of 15 patients and 15 caregivers. As of manuscript submission, no patients or caregivers have been recruited, and data analysis has not yet started. Data collection is expected to conclude by the end of 2026, and results are anticipated for publication in 2027. Conclusions: This protocol outlines a rigorous, replicable approach to adapting a validated transition readiness measure to POMS. The adapted TRAQ 6.0 will support evidence-based transition planning and inform future psychometric testing and implementation research to improve the care of patients with POMS as they age.
- Open Access
Diagnosis of Multiple Sclerosis Using Multimodal Deep Learning Integrating Lesion and Normal-Appearing White Matter: A Retrospective Study with International Multicentre External Validation
Current multiple sclerosis (MS) diagnosis relies primarily on focal white matter lesions (WMLs), which are frequently mimicked by other conditions. Normal-appearing white matter (NAWM) harbours complementary pathological information but remains clinically underutilised because NAWM alterations are macroscopically occult on routine scans and require non-routine quantitative imaging to visualise. Here, we show that NAWM-related diagnostic information can be recovered from routine structural MRI using a cross-modal deep-learning model. We developed DeepMS, a model co-trained on diffusion and structural MRI that operates solely on structural MRI at deployment. DeepMS achieved ROC-AUCs of 0.968 internally (n=837) and 0.940–0.974 across two international external cohorts (n=293 and n=1,756). In a multi-reader study, DeepMS outperformed the 2024 McDonald criteria imaging biomarkers. DeepMS retained robust performance after digital lesion removal and exhibited NAWM-dominant activation maps. Combined with established imaging biomarkers, DeepMS improved sensitivity (92.1% vs 74.8%) while maintaining high specificity (95.6% vs 92.3%) compared with corresponding biomarker composite based on the 2024 McDonald criteria. By decoding latent NAWM signals from routine scans and integrating them with WML features, this framework can potentially advance MS diagnosis beyond the current lesion-centric paradigm.
Open AccessDiagnosis of Multiple Sclerosis Using Multimodal Deep Learning Integrating Lesion and Normal-Appearing White Matter: A Retrospective Study with International Multicentre External Validation
Current multiple sclerosis (MS) diagnosis relies primarily on focal white matter lesions (WMLs), which are frequently mimicked by other conditions. Normal-appearing white matter (NAWM) harbours complementary pathological information but remains clinically underutilised because NAWM alterations are macroscopically occult on routine scans and require non-routine quantitative imaging to visualise. Here, we show that NAWM-related diagnostic information can be recovered from routine structural MRI using a cross-modal deep-learning model. We developed DeepMS, a model co-trained on diffusion and structural MRI that operates solely on structural MRI at deployment. DeepMS achieved ROC-AUCs of 0.968 internally (n=837) and 0.940–0.974 across two international external cohorts (n=293 and n=1,756). In a multi-reader study, DeepMS outperformed the 2024 McDonald criteria imaging biomarkers. DeepMS retained robust performance after digital lesion removal and exhibited NAWM-dominant activation maps. Combined with established imaging biomarkers, DeepMS improved sensitivity (92.1% vs 74.8%) while maintaining high specificity (95.6% vs 92.3%) compared with corresponding biomarker composite based on the 2024 McDonald criteria. By decoding latent NAWM signals from routine scans and integrating them with WML features, this framework can potentially advance MS diagnosis beyond the current lesion-centric paradigm.
- Open Access
- 26 January 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Transition Readiness in Pediatric Onset Multiple Sclerosis: A Study Protocol for the Adaptation of the Transition Readiness Assessment Questionnaire (Preprint)
BACKGROUND Pediatric-onset multiple sclerosis (POMS) is a chronic, progressive neurologic condition requiring lifelong management and coordinated transition from pediatric to adult care. Evidence-based guidelines identify transition readiness assessment as a core component of successful transition; however, most POMS clinics do not formally assess readiness, and existing tools do not address POMS-specific challenges, such as fluctuating disability, complex treatment regimens, and cognitive impairment. This gap underscores the need for a transition readiness measure tailored to POMS. OBJECTIVE To describe a stakeholder-engaged, implementation science–guided protocol for adapting the Transition Readiness Assessment Questionnaire (TRAQ) to reflect the unique developmental and clinical needs of youth with POMS. METHODS Using adaptation and participatory research as our guiding implementation strategies, surveys will be administered to patients, caregivers, and clinicians to identify barriers and facilitators to transition to adult care and define essential self-management competencies. Survey content will be informed by constructs from the Dynamic Adaptation Process framework and existing TRAQ domains. Identified competencies will be refined using a Delphi consensus process. A multidisciplinary focus group of 8–10 collaborators will review the adapted measure to assess clarity, relevance, and perceived clinical utility. RESULTS This project will generate a consensus-driven set of POMS-specific transition competencies and systematically adapt the TRAQ to the POMS population. CONCLUSIONS This protocol outlines a rigorous, easily replicable approach to adapting a validated transition readiness measure to POMS. The adapted TRAQ will support evidence-based transition planning and inform future psychometric testing and implementation research to improve the care of POMS patients as they age.
- 26 January 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessTransition Readiness in Pediatric Onset Multiple Sclerosis: A Study Protocol for the Adaptation of the Transition Readiness Assessment Questionnaire (Preprint)
BACKGROUND Pediatric-onset multiple sclerosis (POMS) is a chronic, progressive neurologic condition requiring lifelong management and coordinated transition from pediatric to adult care. Evidence-based guidelines identify transition readiness assessment as a core component of successful transition; however, most POMS clinics do not formally assess readiness, and existing tools do not address POMS-specific challenges, such as fluctuating disability, complex treatment regimens, and cognitive impairment. This gap underscores the need for a transition readiness measure tailored to POMS. OBJECTIVE To describe a stakeholder-engaged, implementation science–guided protocol for adapting the Transition Readiness Assessment Questionnaire (TRAQ) to reflect the unique developmental and clinical needs of youth with POMS. METHODS Using adaptation and participatory research as our guiding implementation strategies, surveys will be administered to patients, caregivers, and clinicians to identify barriers and facilitators to transition to adult care and define essential self-management competencies. Survey content will be informed by constructs from the Dynamic Adaptation Process framework and existing TRAQ domains. Identified competencies will be refined using a Delphi consensus process. A multidisciplinary focus group of 8–10 collaborators will review the adapted measure to assess clarity, relevance, and perceived clinical utility. RESULTS This project will generate a consensus-driven set of POMS-specific transition competencies and systematically adapt the TRAQ to the POMS population. CONCLUSIONS This protocol outlines a rigorous, easily replicable approach to adapting a validated transition readiness measure to POMS. The adapted TRAQ will support evidence-based transition planning and inform future psychometric testing and implementation research to improve the care of POMS patients as they age.
- Open Access
- 2 January 2026
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (1)
Childhood adversity, allostatic load and epigenetic signatures in paediatric and adult-onset multiple sclerosis
Childhood adversity is increasingly recognized as a critical modifier of neurologic disorder development and disease severity, including in the neuroimmune disorder multiple sclerosis (MS). While previous studies have linked early-life adversity to increased MS susceptibility and more severe disease, the underlying biological mechanisms remain poorly understood. This study investigated associations between childhood adversity and MS clinical features, with a focus on two potential pathogenic mechanisms: allostatic load and epigenetic modifications. We evaluated 60 consecutively enrolled young adults with MS; 30 with paediatric-onset MS (POMS) and 30 with adult-onset MS (AOMS). At time of enrolment in this cross-sectional study, participants had MS disease duration of 6 years on average. POMS participants were mean 22.09 (2.66) years and AOMS participants were mean 32.41 (2.19) years old. 62% of participants were female. Childhood adversity was defined using a composite index of individual, family and socioeconomic measures captured by the adverse childhood experiences questionnaire, parental education level and estimated household income during childhood. Clinical outcomes included patient-reported SymptoMScreen questionnaire regarding MS symptom burden and MS neurologist-assessed disability using the Expanded Disability Status Scale (EDSS) of the participant’s neurologic exam at the time of enrolment. Circulating biomarkers of allostatic load and genome-wide epigenetic profiles (DNA methylation via RRBS; reduced representation bisulfite sequencing) were also assessed. A history of high childhood adversity was associated with significantly greater patient-reported MS symptom burden (P = 0.001) and higher neurologist-reported EDSS disability scores (P = 0.028), independent of disease duration or timing of treatment initiation. There were no differences between childhood adversity and circulating biomarkers of allostatic load. While childhood adversity was not associated with global epigenetic changes across the entire cohort, stratified analysis revealed divergent methylation patterns by age of MS onset: POMS participants with childhood adversity had increased DNA methylation, whereas AOMS participants with childhood adversity showed decreased methylation compared to individuals without childhood adversity. None of the observed clinical and biologic differences were explained by differences in disease duration or the interval between symptom onset and treatment initiation. Our findings suggest that childhood adversity is associated with increased MS symptom burden and neurologic disability in young adults with MS. Childhood adversity may differentially shape the epigenome, depending on the age of MS onset, with potential implications for disease trajectory and therapeutic vulnerability. These results support the biological embedding of childhood adversity in MS and highlight the need for age- and exposure-sensitive approaches to understanding MS pathogenesis across the lifespan.
- 2 January 2026
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (1)
Open AccessChildhood adversity, allostatic load and epigenetic signatures in paediatric and adult-onset multiple sclerosis
Childhood adversity is increasingly recognized as a critical modifier of neurologic disorder development and disease severity, including in the neuroimmune disorder multiple sclerosis (MS). While previous studies have linked early-life adversity to increased MS susceptibility and more severe disease, the underlying biological mechanisms remain poorly understood. This study investigated associations between childhood adversity and MS clinical features, with a focus on two potential pathogenic mechanisms: allostatic load and epigenetic modifications. We evaluated 60 consecutively enrolled young adults with MS; 30 with paediatric-onset MS (POMS) and 30 with adult-onset MS (AOMS). At time of enrolment in this cross-sectional study, participants had MS disease duration of 6 years on average. POMS participants were mean 22.09 (2.66) years and AOMS participants were mean 32.41 (2.19) years old. 62% of participants were female. Childhood adversity was defined using a composite index of individual, family and socioeconomic measures captured by the adverse childhood experiences questionnaire, parental education level and estimated household income during childhood. Clinical outcomes included patient-reported SymptoMScreen questionnaire regarding MS symptom burden and MS neurologist-assessed disability using the Expanded Disability Status Scale (EDSS) of the participant’s neurologic exam at the time of enrolment. Circulating biomarkers of allostatic load and genome-wide epigenetic profiles (DNA methylation via RRBS; reduced representation bisulfite sequencing) were also assessed. A history of high childhood adversity was associated with significantly greater patient-reported MS symptom burden (P = 0.001) and higher neurologist-reported EDSS disability scores (P = 0.028), independent of disease duration or timing of treatment initiation. There were no differences between childhood adversity and circulating biomarkers of allostatic load. While childhood adversity was not associated with global epigenetic changes across the entire cohort, stratified analysis revealed divergent methylation patterns by age of MS onset: POMS participants with childhood adversity had increased DNA methylation, whereas AOMS participants with childhood adversity showed decreased methylation compared to individuals without childhood adversity. None of the observed clinical and biologic differences were explained by differences in disease duration or the interval between symptom onset and treatment initiation. Our findings suggest that childhood adversity is associated with increased MS symptom burden and neurologic disability in young adults with MS. Childhood adversity may differentially shape the epigenome, depending on the age of MS onset, with potential implications for disease trajectory and therapeutic vulnerability. These results support the biological embedding of childhood adversity in MS and highlight the need for age- and exposure-sensitive approaches to understanding MS pathogenesis across the lifespan.
- Open Access
- 19 December 2025
- Published by Elsevier in Equity Neuroscience
- Vol. 2 (1)
Finding community for early career health equity researchers
- 19 December 2025
- Published by Elsevier in Equity Neuroscience
- Vol. 2 (1)
Open AccessFinding community for early career health equity researchers
- Open Access
- 6 November 2025
- Published by Wiley in Annals of Neurology
- Vol. 99 (3) , 715-729
Real‐World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease‐Modifying Therapy in Pediatric Multiple Sclerosis
Objective: To assess real‐world effectiveness of switching disease‐modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity. Methods: Of 2615 pediatric‐onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric MS Centers, those with MS/CIS on initial therapy with a platform injectable who switched to another class of platform injectable, oral or infusion DMT were analyzed. Relapse rate was modeled with negative binomial regression, adjusted for preidentified confounders. Results: A total of 212 children switched DMT before age 18 (67% female, 95% MS). Ninety‐three switched from injectable to injectable, 76 injectable to oral, and 43 injectable to infusion. Switchers to oral or infusion were older at onset (injectable 12.3 years, oral 13.5 years, and infusion 14.2 years) and switch (injectable 14.6 years, oral 16.0 years, and infusion 15.7 years). Switchers to infusion DMT were more likely to have enhancing lesions (injectable 45%, oral 28%, and infusion 67%). Compared to injectable (annualized relapse rate [ARR] = 0.88, 95% confidence interval [CI] = 0.52–1.48), relapse rates were lower for injectable to oral (ARR = 0.34, 95% CI = 0.20–0.57; rate ratio: 0.38, 95% CI = 0.21–0.69) and injectable to infusion (ARR = 0.18, 95% CI = 0.09–0.37; rate ratio: 0.21, 95% CI = 0.10–0.44) ( p < 0.001). Adjusted number needed to treat in person‐years to prevent 1 relapse with oral over injectable was 1.84 (95% CI = 1.03–8.69) and infusion over injectable 1.43 (95% CI = 1.00–3.88). Interpretation: Switching from platform injectable to oral or infusion compared to other platform injectable DMT led to better disease control in pediatric MS. Long‐term safety data are required. ANN NEUROL 2026;99:715–729
- 6 November 2025
- Published by Wiley in Annals of Neurology
- Vol. 99 (3) , 715-729
Open AccessReal‐World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease‐Modifying Therapy in Pediatric Multiple Sclerosis
Objective: To assess real‐world effectiveness of switching disease‐modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity. Methods: Of 2615 pediatric‐onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric MS Centers, those with MS/CIS on initial therapy with a platform injectable who switched to another class of platform injectable, oral or infusion DMT were analyzed. Relapse rate was modeled with negative binomial regression, adjusted for preidentified confounders. Results: A total of 212 children switched DMT before age 18 (67% female, 95% MS). Ninety‐three switched from injectable to injectable, 76 injectable to oral, and 43 injectable to infusion. Switchers to oral or infusion were older at onset (injectable 12.3 years, oral 13.5 years, and infusion 14.2 years) and switch (injectable 14.6 years, oral 16.0 years, and infusion 15.7 years). Switchers to infusion DMT were more likely to have enhancing lesions (injectable 45%, oral 28%, and infusion 67%). Compared to injectable (annualized relapse rate [ARR] = 0.88, 95% confidence interval [CI] = 0.52–1.48), relapse rates were lower for injectable to oral (ARR = 0.34, 95% CI = 0.20–0.57; rate ratio: 0.38, 95% CI = 0.21–0.69) and injectable to infusion (ARR = 0.18, 95% CI = 0.09–0.37; rate ratio: 0.21, 95% CI = 0.10–0.44) ( p < 0.001). Adjusted number needed to treat in person‐years to prevent 1 relapse with oral over injectable was 1.84 (95% CI = 1.03–8.69) and infusion over injectable 1.43 (95% CI = 1.00–3.88). Interpretation: Switching from platform injectable to oral or infusion compared to other platform injectable DMT led to better disease control in pediatric MS. Long‐term safety data are required. ANN NEUROL 2026;99:715–729
- 5 November 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 175, 50-57
Incorporating Measures of Cognitive Processing Speed and Brain Volume in Clinical Management of Pediatric Onset Multiple Sclerosis
- 5 November 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 175, 50-57
Incorporating Measures of Cognitive Processing Speed and Brain Volume in Clinical Management of Pediatric Onset Multiple Sclerosis